Australia's most trusted
source of pharma news
Friday, 14 February 2025
Posted 10 July 2024 PM
Health Minister Mark Butler announced this morning that the Federal Government will cover the costs of Norgine's unapproved brain cancer treatment until the company establishes a compassionate access scheme while it pursues the necessary approvals for a PBS listing.
The decision follows mounting pressure from parents seeking the medicine known as DFMO, short for difluoromethylornithine, for their children diagnosed with high-risk neuroblastoma.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.